We tested potent small molecule FASN inhibitors including TVB-2640 (denifanstat) in liver, immune and fibrogenic cells ex vivo, and in mouse models of NASH and liver fibrosis. Here, FASN is linked to metabolic dysfunction-associated steatohepatitis.